Aflibercept 8 mg may lower treatment costs in nAMD and DME compared with faricimab
A new cost analysis suggests that aflibercept 8 mg could provide economic advantages over faricimab in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Using data from pivotal clinical trials (PULSAR, PHOTON, TENAYA, LUCERNE, YOSEMITE, and RHINE), researchers modeled direct and indirect costs over a 3- to 5-year period. The analysis incorporated drug acquisition prices, monitoring expenses, and patient/caregiver time and travel.
On average, patients receiving aflibercept 8 mg required fewer injections than those treated with faricimab (12.25 vs 14.80 for nAMD and 11.80 vs 15.65 for DME) over 3 years. This reduction translated to lower overall costs, with savings of approximately $1,979 per patient with nAMD and $6,033 per patient with DME. These cost benefits persisted through year 5.
Reference
Kuznik A, Coughlan A, Pinsent A, et al. Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US. Ophthalmol Ther. 2025;doi: 10.1007/s40123-025-01236-6. Epub ahead of print. PMID: 40971061.
Related Content
